NCT04484506View on ClinicalTrials.gov

Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 20, 2011

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2025

Conditions
NK/T Cell Lymphoma Nos
Interventions
DRUG

pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone

Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Peking University International Hospital

OTHER

collaborator

Hebei Medical University Fourth Hospital

OTHER

collaborator

Jiangxi Provincial Cancer Hospital

OTHER

lead

Peking University

OTHER